I-Mab ADR (IMAB) News
Filter IMAB News Items
IMAB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest IMAB News From Around the Web
Below are the latest news stories about I-MAB that investors may wish to consider to help them evaluate IMAB as an investment opportunity.
Positive week for I-Mab (NASDAQ:IMAB) institutional investors who lost 91% over the past yearTo get a sense of who is truly in control of I-Mab ( NASDAQ:IMAB ), it is important to understand the ownership... |
I-Mab First Half 2022 Earnings: Misses ExpectationsI-Mab ( NASDAQ:IMAB ) First Half 2022 Results Key Financial Results Revenue: CN¥51.9m (up 192% from 1H 2021). Net loss... |
I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that two poster presentations featuring preclinical and translational research data of lemzoparlimab, will be presented at the 64th American Society of Hematology (ASH) Annual Meeting, taking place December 10-13, 2022, in New Orleans, Louisiana. |
I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will present new preclinical data of its core assets lemzoparlimab and uliledlimab, respectively, at the 37th Society for Immunotherapy of Cancer's (SITC) Annual Meeting in Boston, MA, as well as virtually November 8-12, 2022. |
I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic SyndromeI-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has successfully completed an End-of-Phase 2 (EoP2) meeting with the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA), and has obtained approval from the CDE to initiate a Phase 3 registrational trial evaluating lemzoparlimab, a novel CD47 antibody, in combination with |
I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announces encouraging data from its Phase 2 clinical trial (NCT04202003) of lemzoparlimab (also known as TJC4) in combination with azacitidine (AZA) in patients with newly diagnosed higher risk myelodysplastic syndrome (HR-MDS), presented in an oral presentation on September 10 at the European Society for Medical Oncology (ESMO) |
I-Mab Announces Oral Presentation of Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the results from its Phase 2 clinical study of lemzoparlimab (also known as TJC4) in combination with azacitidine (AZA) in patients with higher risk myelodysplastic syndrome (HR-MDS) will be featured in a proffered paper presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2022, on Sa |
Analysts Conflicted on These Healthcare Names: Sangamo Biosciences (SGMO) and I-MAB (IMAB)Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sangamo Biosciences (SGMO – Research Report) and I-MAB (IMAB – Research Report). Sangamo Biosciences (SGMO) Wedbush analyst Andreas Argyrides reiterated a Hold rating on Sangamo Biosciences today and set a price target of $5.00. The company's shares closed last Tuesday at $5.33. According to TipRanks. |
Needham Sticks to Its Buy Rating for I-MAB (IMAB)Needham analyst Gil Blum reiterated a Buy rating on I-MAB (IMAB - Research Report) today and set a price target of $33.00. The company's shares opened today at $6.02.Blum covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, I-MAB, and Aeglea Biotherapeutics. According to TipRanks, Blum has an average return of -7.6% and a 38.32% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for I-MAB with a $51.50 average price target. |
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced financial results for the six months ended June 30, 2022, and provided key business updates. |